Company / SG&A Expense
Apogee Therapeutics, Inc. SG&A Expense History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$49.0M
FY2024
5-year range
$2.9M / $49.0M
FY2022-FY2024
Trend
+99.4%
vs FY2023
Sector context
#161 of 213
Health Care
What the data says
Apogee Therapeutics, Inc.'s sg&a expense of $49M is lower than 76% of companies in the Health Care sector (FY2024). Increased from $3M to $49M over the past 2 years.
Based on SEC 10-K filings.
$49M in FY2024.
Increased from $3M to $49M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 213This company $49.0M Sector average $722.3M
▼
-93.2% below sector average
Key checks
Key Insights
- In FY2024, sg&a expense increased 99.4% year-over-year.
- Ranks #161 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $49.0M | +99.4% |
| FY2023 | $24.6M | +735.7% |
| FY2022 | $2.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026